Definium Therapeutics reported its full-year 2025 financial results and provided business updates. Cash, cash equivalents, and investments totaled $411.6 million as of December 31, 2025, an increase from $273.7 million as of December 31, 2024. The company's cash runway is expected to fund operations into 2028. Enrollment for the Emerge (Phase 3 MDD) study is complete, with topline data anticipated in late 2Q 2026, sooner than previously expected. The Voyage (Phase 3 GAD) study is approximately 80% enrolled, with no change in sample size required, and topline data anticipated in early 3Q 2026. Enrollment for the Panorama (Phase 3 GAD) study is on track, with topline data expected in 2H 2026. An equity financing completed in 4Q 2025 generated approximately $259 million in gross proceeds. DT120 has received FDA Breakthrough Designation for Generalized Anxiety Disorder (GAD). The company initiated a Phase 2a study for DT402 in Autism Spectrum Disorder (ASD) in 4Q 2025, with initial data anticipated in 2026. Research and Development (R&D) expenses increased to $117.7 million for the year ended December 31, 2025, from $65.3 million in 2024. General and Administrative (G&A) expenses increased to $48.6 million for the year ended December 31, 2025, from $38.6 million in 2024. Net loss for the year ended December 31, 2025, was $183.8 million, compared to $108.7 million in 2024.